Mylan and Biocon's Semglee (insulin glargine injection) is now the second approved "follow-on" biologic of Sanofi's Lantus. Adults with Type 2 diabetes, and adult and pediatric patients with Type 1 ...
Semglee™ (insulin glargine injection; Mylan and Biocon Biologics) is now available to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.
Add Yahoo as a preferred source to see more of our stories on Google. Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results